Ranbaxy net falls 5% despite 15% rise in topline - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy net falls 5% despite 15% rise in topline

Jul 29, 2000

Despite a 15% rise in the topline, Ranbaxy's bottomline has dropped 5% in the second quarter of the current year.

(Rs m)2QFY992QFY00Change
Sales 3,695 4,236 14.6%
Profit before Tax464437-5.8%
Tax 39 33 -15.4%
Profit after Tax/(Loss) 425 404 -4.9%
Net profit margin (%)11.5%9.5% 
No. of Shares (m) (eoy)115.9115.9 
Diluted no. of shares (m)115.9115.9 
Diluted Earnings per share*14.713.9 

The reasons for this are not far to seek. With dependence on antibiotics at around 55% of the company's turnover, the margins are bound to be under pressure due to heavy congestion in the antibiotics market.

Surprisingly, the company's domestic sales have grown over 16.5% in the current quarter while the exports have grown by 12.6%. One reason for this is the fact that the company is changing the compostion of its exports from bulk actives to generic formulations and in the transition period the growth has fallen.

This is the second consecutive quarter where the company's profit has fallen and with the overall pharmaceutical market, especially the antibiotic market, still in a swoon not much can be expected from the remaining quarters as well. Perhaps the only way out for the company would be the licensing of the BPH compound, but around nine months ago at an analysts meet the management had clarified that the development of the compound would take around eighteen months.

The stock quotes at Rs 551 which implies an earning multiple of 39.6 times second quarter annualised earnings.

Equitymaster requests your view! Post a comment on "Ranbaxy net falls 5% despite 15% rise in topline ". Click here!


More Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks